289 related articles for article (PubMed ID: 31399507)
1. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
2. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.
Xu D; Li F; Zhang M; Zhang J; Liu C; Hu MY; Zhong ZY; Jia LL; Wang DW; Wu J; Liu L; Liu XD
Acta Pharmacol Sin; 2014 Sep; 35(9):1215-25. PubMed ID: 25152023
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
4. Short-chain fatty acids oppositely altered expressions and functions of intestinal cytochrome P4503A and P-glycoprotein and affected pharmacokinetics of verapamil following oral administration to rats.
Zhang J; Xie Q; Kong W; Wang Z; Wang S; Zhao K; Chen Y; Liu X; Liu L
J Pharm Pharmacol; 2020 Mar; 72(3):448-460. PubMed ID: 31863502
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.
Yang Y; Li P; Zhang Z; Wang Z; Liu L; Liu X
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987693
[TBL] [Abstract][Full Text] [Related]
6. Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2.
Shu N; Hu M; Liu C; Zhang M; Ling Z; Zhang J; Xu P; Zhong Z; Chen Y; Liu L; Liu X
Xenobiotica; 2016 Oct; 46(10):875-81. PubMed ID: 26864241
[TBL] [Abstract][Full Text] [Related]
7. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
8. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
9. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
10. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus.
Liu H; Liu L; Li J; Mei D; Duan R; Hu N; Guo H; Zhong Z; Liu X
Drug Metab Dispos; 2012 Jun; 40(6):1104-12. PubMed ID: 22393122
[TBL] [Abstract][Full Text] [Related]
11. The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1.
Shu N; Hu M; Ling Z; Liu P; Wang F; Xu P; Zhong Z; Sun B; Zhang M; Li F; Xie Q; Liu X; Liu L
Sci Rep; 2016 Sep; 6():33072. PubMed ID: 27624558
[TBL] [Abstract][Full Text] [Related]
12. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
13. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.
Yao H; Gu J; Shan Y; Wang Y; Chen X; Sun D; Guo Y
Biochem Pharmacol; 2020 Oct; 180():114142. PubMed ID: 32653591
[TBL] [Abstract][Full Text] [Related]
16. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Yim CS; Jeong YS; Lee SY; Pyeon W; Ryu HM; Lee JH; Lee KR; Maeng HJ; Chung SJ
Drug Metab Dispos; 2017 Mar; 45(3):246-259. PubMed ID: 28069721
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
18. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
[TBL] [Abstract][Full Text] [Related]
19. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Uno S; Kawase A; Tsuji A; Tanino T; Iwaki M
Drug Metab Pharmacokinet; 2007 Aug; 22(4):313-21. PubMed ID: 17827786
[TBL] [Abstract][Full Text] [Related]
20. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats.
Lin CH; Hsu KW; Chen CH; Uang YS; Lin CJ
Biochem Pharmacol; 2017 Oct; 142():216-228. PubMed ID: 28636885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
